Skip to main content

Table 1 Participant characteristics in development/calibration dataset (STATCOPE = Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD) and validation dataset (MACRO = Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease)

From: Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations

  STATCOPE
(n = 853)
MACRO
(n = 1018)
Age, years 62 ± 8 66 ± 9
Male sex - no. (%) 479 (56%) 606 (60%)
Race - no. (%)
 Black 177 (21%) 138 (14%)
 White 651 (77%) 830 (82%)
 Other 20 (2%) 50 (5%)
BMI, kg/m2 27.2 ± 6.9 27.8 ± 6.2
Alcohol consumption, drinks per day 0.48 ± 0.85 0.40 ± 1.03
Currently smoking - no. (%) 257 (30%) 222 (22%)
Oxygen use - no. (%) 408 (48%) 604 (59%)
ED visit or hospitalized for AECOPD in year prior to enrollment - no. (%) 434 (51%) 517 (51%)
Steroids or antibiotics in previous year - no. (%) 715 (84%) 865 (85%)
FEV1/FVC ratio, % 44 ± 13 43 ± 13
Post-bronchodilator FEV1, L 1.19 ± 0.57 1.12 ± 0.51
Post-bronchodilator FEV1, % predicted 42 ± 18 40 ± 16
GOLD category - no. (%)
 1 1 (0.1%)
 2 278 (33%) 277 (27%)
 3 293 (35%) 410 (40%)
 4 277 (33%) 327 (32%)
Mean Serum Bilirubin (mg/dL)
 Enrollment/baseline 0.65 ± 0.30 0.64 ± 0.29
 Month 1 0.63 ± 0.28
 Month 3 0.63 ± 0.28
 Month 6 0.62 ± 0.28 0.63 ± 0.27
 Month 9 0.63 ± 0.28
 Month 12 0.65 ± 0.28 0.64 ± 0.28
 Month 18 0.63 ± 0.27
 Month 24 0.65 ± 0.28
  1. Abbreviations: AECOPD acute exacerbation of chronic obstructive pulmonary disease, BMI body mass index, ED emergency department, FEV 1 forced expiratory volume in one second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease